Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Change Control Procedure – V 2.0

Posted on By

Elixir Department: SOP for Change Control Procedure – V 2.0

Standard Operating Procedure for Change Control Procedure in Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/244/2025
Supersedes SOP/ELX/244/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To define a formal system for initiating, evaluating, approving, implementing, and reviewing changes that may impact the quality, safety, or efficacy of elixir products and associated processes in compliance with cGMP and regulatory expectations.

2. Scope

This SOP applies to all proposed changes related to facilities, utilities, equipment, materials, documents, processes, test methods, and computer systems involved in elixir manufacturing, testing, and distribution.

3. Responsibilities

  • Initiator (Any Department):
    • Identify the need for change and fill out the Change Control Request Form (Annexure-1).
  • Department Head:
    • Perform initial assessment of proposed change and submit for QA review.
  • QA Officer:
    • Assign change control number, perform risk assessment, and coordinate cross-functional review.
  • Change Control Committee (CCC):
    • Evaluate and approve/reject major changes after full impact assessment.
See also  Elixir Department: SOP for Alarm Handling on Mixing Equipment - V 2.0

4. Accountability

The QA Head is accountable for maintaining the change control system, ensuring timely execution, documentation, and regulatory compliance.

5. Procedure

5.1 Types of Change

  • Minor Change: Change with minimal impact, e.g., equipment ID renumbering, editorial document corrections.
  • Major Change: Change with potential regulatory, product quality, or validation impact, e.g., formulation modification, facility layout redesign, vendor replacement.

5.2 Change Request Initiation

  1. The initiator fills the Change Control Request Form (Annexure-1) and submits it to QA.
  2. QA assigns a unique Change Control Number (e.g., CC/ELX/2025/001) and logs in Change Control Register (Annexure-2).

5.3 Impact Assessment

  1. QA coordinates with affected departments (Production, QC, Engineering, Regulatory, IT) to perform impact assessment.
  2. Evaluate impact on:
    • Product quality and safety
    • GMP compliance
    • Validation status
    • Regulatory filings
    • Training and documentation

See also  Elixir Department: SOP for Cleaning After Batch Failure - V 2.0

5.4 Approval

  1. Minor changes may be approved by QA and department head.
  2. Major changes must be reviewed by the Change Control Committee (CCC) and require QA Head approval.

5.5 Implementation

  1. Assigned teams execute the change as per action plan and timelines.
  2. Update impacted SOPs, protocols, validation documents, and train concerned personnel.

5.6 Verification and Closure

  1. QA verifies implementation and supporting documents.
  2. Post-change review is conducted to confirm intended outcomes.
  3. QA signs off the closure section of Change Control Form.

5.7 Change Control Metrics

  1. QA shall review monthly open and closed changes, and include data in quality metrics.
  2. Delayed closures must be escalated with justification to senior QA.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CCC: Change Control Committee
  • GMP: Good Manufacturing Practice

7. Documents

  1. Change Control Request Form (Annexure-1)
  2. Change Control Register (Annexure-2)
  3. Risk Assessment Worksheet

See also  Elixir Department: SOP for Identification of API by IR Spectroscopy - V 2.0

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211.100 – Written Procedures and Change Control
  • WHO Technical Report Series No. 986 – Annex 2

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Change Control Request Form

Change Control No. Date Initiator Department Description of Change Type (Minor/Major)
CC/ELX/2025/001 11/04/2025 Rajesh Kumar Production Change in elixir batch size from 500L to 600L Major

Annexure-2: Change Control Register

Change No. Date Department Status Implementation Date Closed By
CC/ELX/2025/001 11/04/2025 Production Closed 20/04/2025 Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP Creation QA Head
11/04/2025 2.0 Updated with CCC involvement and minor/major classification Compliance with ICH Q10 QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Analytical Method Development: SOP for Handling Method Development Failures – V 2.0
Next Post: Analytical Method Development: SOP for Investigation of Out-of-Trend (OOT) Results – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version